DnB Asset Management
GPCR icon

DnB Asset Management’s Structure Therapeutics GPCR Stock Holding History

DnB Asset Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$579K Buy
10,779
+2,591
+32% +$115K ﹤0.01% 746
2026
Q1 		$395K Sell
8,188
-4,451
-35% -$305K ﹤0.01% 849
2025
Q4 		$879K Sell
12,639
-249
-2% -$10.2K ﹤0.01% 647
2025
Q3 		$361K Buy
12,888
+2,253
+21% +$44.9K ﹤0.01% 686
2025
Q2 		$221K Buy
+10,635
New +$234K ﹤0.01% 692

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

DnB Asset Management's GPCR Position: Q2 2026 in Review

DnB Asset Management increased its Structure Therapeutics (GPCR) stake by 32% in Q2 2026, buying an estimated $115K and bringing the position to 10,779 shares worth $579K. The position accounts for ﹤0.01% of the portfolio, ranked #746.

DnB Asset Management first reported a position in GPCR in Q2 2025 and has held it in 5 quarters since. The position peaked at $879K in Q4 2025. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • DnB Asset Management held 10,779 shares of Structure Therapeutics worth $579K as of Q2 2026.
  • DnB Asset Management bought 2,591 Structure Therapeutics shares in Q2 2026, an estimated $115K.
  • Structure Therapeutics made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #746 holding.
  • DnB Asset Management first reported a position in Structure Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • DnB Asset Management's Structure Therapeutics position peaked at $879K in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.